INSMED Inc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Insmed (INSM) reported Q2 2026 revenue of $425.5M, up 296% YoY, with net loss narrowing to $13.2M. BRINSUPRI sales reached $309.2M, up 49% QoQ. The company raised full-year BRINSUPRI guidance to $1.25B-$1.40B. Insmed also increased its peak revenue estimate for lead programs to over $14B. Expenses rose due to commercial buildout and R&D spending.
Insmed (INSM) received approval for BRINSUPRI in Japan, adding to U.S. and European clearances. Shares rose 2.78% to $121.84, with a 30-day return of 23.57% but a YTD decline of 31.21%. Analysts suggest a fair value of $197.14, indicating potential undervaluation, but risks include approval delays and reimbursement challenges.
Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
Over the past 7 days, alphai's AI scored 1 news story mentioning INSM (INSMED Inc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent INSM coverage spans earnings, regulation and technology.
In the last 30 days, INSM insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($32.6M). The most active reporter was SHAROKY MELVIN MD with 1 filing.
Earnings beat and raised guidance likely support a near‑term price rally.
Regulatory approval in Japan expands Insmed's addressable market and could boost revenue.
Adds a new indication, supportive for INSM.
Regulatory approval in Japan removes a major hurdle for Brinsupri, supporting higher valuation.
Approval opens a new market for Insmed, likely boosting revenue and share price.
alphai scores every news story that mentions INSM with an AI model for sentiment and relevance, and aggregates insider trades from INSMED Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Insmed (INSM) reported Q2 2026 revenue of $425.5M, up 296% YoY, with net loss narrowing to $13.2M. BRINSUPRI sales reached $309.2M, up 49% QoQ. The company raised full-year BRINSUPRI guidance to $1.25B-$1.40B. Insmed also increased its peak revenue estimate for lead programs to over $14B. Expenses rose due to commercial buildout and R&D spending.
2 min readInsmed (INSM) received approval for BRINSUPRI in Japan, adding to U.S. and European clearances. Shares rose 2.78% to $121.84, with a 30-day return of 23.57% but a YTD decline of 31.21%. Analysts suggest a fair value of $197.14, indicating potential undervaluation, but risks include approval delays and reimbursement challenges.
3 min readGilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
3 min readMizuho raised its price target for Insmed (INSM) to $195, citing Japan's approval of Brinsupri. The stock trades at $123.98, with a market cap of $27.1B. Insmed reported strong Q2 2026 revenue, raising guidance for Brinsupri and TPIP. Analysts maintain a strong buy rating, with upward earnings revisions.
2 min readInsmed Inc. (INSM) announced Japan's approval of BRINSUPRI® (brensocatib) for treating non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12+. The approval is based on Phase 3 ASPEN study results showing reduced pulmonary exacerbations and lower lung function decline. BRINSUPRI is now approved in the U.S., Europe, and Japan.
2 min readInsmed Inc. (INSM) shares fell 4.3% due to profit-taking after a recent rally and insider stock sales. The company reported Q2 2026 revenue of $425.5M and raised guidance. Insiders, including the COO and CMO, sold shares recently. No new negative company news was reported.
2 min readSHAROKY MELVIN MD sold 5,000 indirectly-held shares of INSMED Inc (INSM) at $127.53 ($0.64M total) on 2026-08-17.
1 min readInsmed Inc. (INSM) reported a sharply narrowed net loss of $13.24M in Q2 2026, down from $321.69M a year earlier, with loss per share at $0.06 vs. $1.70. The company's H1 2026 net loss also improved to $176.81M from $578.27M, indicating lower cash burn. Insmed's investment narrative focuses on its respiratory portfolio, particularly brensocatib, with guidance projecting $1B in 2026 BRINSUPRI revenue and $450M-$470M from ARIKAYCE. The company aims for $4.1B revenue and $1B earnings by 2029, requi
2 min readSimply Wall St reports Insmed (INSM) posted Q2 2026 results with a narrower net loss and loss per share versus a year earlier. The stock rose 3.7% in one day and 18.46% over 30 days, though it remains down YTD. The article cites a $128.32 price versus a $197.14 fair value estimate and highlights brensocatib and upcoming clinical milestones.
7 min readPadonia LLC, linked to Melvin Sharoky, filed a Form 144 notice for a proposed sale of up to 5,000 shares of Insmed Inc. common stock (NASDAQ: INSM). The filing cites an approximate aggregate market value of $637,636.84 and references a prior open-market purchase of 10,000 shares on May 15, 2023.
2 min read
